Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May-Jun;15(3):284-290.
doi: 10.4103/apc.apc_157_21. Epub 2022 Nov 16.

Hyperviscosity syndrome revisited

Debasree Gangopadhyay  1 , Mahua Roy  1 , Somrita Laha  1 , Debabrata Nandi  1 , Rhitajyoti Sengupta  2 , Amitabha Chattopadhyay  3
Affiliations

Hyperviscosity syndrome revisited

Debasree Gangopadhyay et al. Ann Pediatr Cardiol. 2022 May-Jun.

Abstract

Secondary erythrocytosis occurs in cyanotic heart disease as a physiological response to chronic hypoxia, and this leads to hyperviscosity and various complications of the same. Microvascular stasis due to hyperviscosity results in symptoms including headache, fatigue, paraesthesia, and loss of vision. An important and dreadful feature of hyperviscosity is overt thrombosis in organ systems, resulting in cerebrovascular accident and myocardial infarction. Limited body iron store in a state of secondary erythrocytosis brings forth iron-deficient microcytic red cells; these being more rigid and less deformable than normocytic cells, further aggravate vascular occlusion. The management of hyperviscosity syndrome starts with intravenous hydration and correction of latent iron deficiency. However, therapeutic phlebotomy may be employed as a rescue measure if symptoms persist despite correction of dehydration and anemia. We present a series of four patients with uncorrected cyanotic congenital heart disease who presented with a spectrum of features of hyperviscosity and discuss pathophysiology, clinical features, and management of hyperviscosity in detail.

Keywords: Cyanotic congenital heart disease; grown-up congenital heart; hyperviscosity syndrome; iron deficiency; phlebotomy; secondary erythrocytosis.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Marked ST segment depression in anterior, lateral and inferior leads
Figure 2
Figure 2
ECG from same patient as in Figure 1. ST changes improve after conservative treatment
See this image and copyright information in PMC

References

    1. Rose SS, Shah AA, Hoover DR, Saidi P. Cyanotic congenital heart disease (CCHD) with symptomatic erythrocytosis. J Gen Intern Med. 2007;22:1775–7. - PMC - PubMed
    1. Perloff JK, Rosove MH, Child JS, Wright GB. Adults with cyanotic congenital heart disease: Hematologic management. Ann Intern Med. 1988;109:406–13. - PubMed
    1. Kotby AA, Mamdouh NM, Eissa DS, Ahmed NT. Risk factors for thrombosis in children with cyanotic congenital heart disease. J Med Sci Clin Res. 2016;04(10):13175–83. doi: 10.18535/jmscr/v4i10.44.
    1. Broberg CS, Jayaweera AR, Diller GP, Prasad SK, Thein SL, Bax BE, et al. Seeking optimal relation between oxygen saturation and hemoglobin concentration in adults with cyanosis from congenital heart disease. Am J Cardiol. 2011;107:595–9. - PubMed
    1. Pillai AA, Fazal S, Babiker HM. StatPearls. Treasure Island (FL): StatPearls Publishing; 2021. [Last updated on 2021 Jun 02]. Polycythemia. Available from: https://www.ncbi.nlm.nih.gov/books/NBK526081/